Alpine Woods Capital Investors’s TherapeuticsMD TXMD Stock Holding History

Alpine Woods Capital Investors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-800	Closed	-$145K	–	278
2019 Q3	$145K	Hold	800	–	–	0.03%	251
2019 Q2	$104K	Hold	800	–	–	0.02%	268
2019 Q1	$195K	Buy	800 +460	+135%	+$122K	0.04%	242
2018 Q4	$65K	Hold	340	–	–	0.02%	271
2018 Q3	$112K	Hold	340	–	–	0.02%	244
2018 Q2	$106K	Buy	340 +100	+42%	+$30.5K	0.02%	240
2018 Q1	$58K	Hold	240	–	–	﹤0.01%	391
2017 Q4	$72K	Hold	240	–	–	﹤0.01%	439
2017 Q3	$64K	Hold	240	–	–	﹤0.01%	445
2017 Q2	$63K	Hold	240	–	–	﹤0.01%	440
2017 Q1	$86K	Hold	240	–	–	﹤0.01%	446
2016 Q4	$69K	Hold	240	–	–	﹤0.01%	439
2016 Q3	$82K	Hold	240	–	–	﹤0.01%	419
2016 Q2	$102K	Sell	240 -80	-25%	-$33K	0.01%	405
2016 Q1	$102K	Hold	320	–	–	0.01%	410
2015 Q4	$166K	Sell	320 -280	-47%	-$103K	0.01%	434
2015 Q3	$176K	Hold	600	–	–	0.01%	451
2015 Q2	$236K	Hold	600	–	–	0.01%	418
2015 Q1	$182K	Buy	600 +120	+25%	+$29.3K	0.01%	430
2014 Q4	$107K	Hold	480	–	–	0.01%	433
2014 Q3	$111K	Hold	480	–	–	0.01%	446
2014 Q2	$106	Buy	+480	New	+$107K	﹤0.01%	436

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alpine Woods Capital Investors's TXMD Position: Q4 2019 in Review

Alpine Woods Capital Investors sold out of TherapeuticsMD (TXMD) in Q4 2019, closing a stake of 800 shares — an estimated $145K sold.

Alpine Woods Capital Investors first reported a position in TXMD in Q2 2014 and held it in 22 quarters. The position peaked at $236K in Q2 2015. 168 funds tracked by Wall St. Rank hold TXMD as of Q4 2019.

Alpine Woods Capital Investors reported no remaining TherapeuticsMD position as of Q4 2019 after selling out during the quarter.
Alpine Woods Capital Investors sold 800 TherapeuticsMD shares in Q4 2019, an estimated $145K.
Alpine Woods Capital Investors first reported a position in TherapeuticsMD in Q2 2014 and held it in 22 quarters.
Alpine Woods Capital Investors's TherapeuticsMD position peaked at $236K in Q2 2015.
168 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2019.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2019, filed 7 Feb 2020.